Stifel Nicolaus lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report sent to investors on Thursday, The Fly reports. They currently have $23.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $55.00.
A number of other research firms also recently commented on SUPN. Cowen set a $50.00 target price on Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 7th. ValuEngine downgraded Supernus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, November 6th. Jefferies Financial Group downgraded Supernus Pharmaceuticals from a buy rating to a hold rating and decreased their target price for the stock from $46.00 to $23.00 in a research report on Wednesday, November 6th. Mizuho reiterated a buy rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, August 7th. Finally, TheStreet downgraded Supernus Pharmaceuticals from a b- rating to a c+ rating in a research report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of Hold and an average target price of $46.50.
Shares of NASDAQ:SUPN traded up $0.13 during mid-day trading on Thursday, reaching $21.84. The stock had a trading volume of 847,513 shares, compared to its average volume of 581,150. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The company has a market cap of $1.53 billion, a P/E ratio of 10.65, a price-to-earnings-growth ratio of 1.02 and a beta of 1.63. Supernus Pharmaceuticals has a 1 year low of $19.35 and a 1 year high of $49.25. The business’s 50 day moving average price is $26.80 and its 200 day moving average price is $30.29.
In related news, CEO Jack A. Khattar acquired 7,200 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were acquired at an average cost of $26.39 per share, for a total transaction of $190,008.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.57% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Patriot Financial Group Insurance Agency LLC purchased a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $33,000. Private Capital Group LLC grew its stake in shares of Supernus Pharmaceuticals by 108.0% during the second quarter. Private Capital Group LLC now owns 1,379 shares of the specialty pharmaceutical company’s stock valued at $83,000 after buying an additional 716 shares during the last quarter. Point72 Hong Kong Ltd grew its stake in shares of Supernus Pharmaceuticals by 324.1% during the second quarter. Point72 Hong Kong Ltd now owns 1,692 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 1,293 shares during the last quarter. First Mercantile Trust Co. grew its stake in shares of Supernus Pharmaceuticals by 31.5% during the third quarter. First Mercantile Trust Co. now owns 2,173 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 520 shares during the last quarter. Finally, Redhawk Wealth Advisors Inc. bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $202,000. Institutional investors and hedge funds own 99.14% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Featured Article: What is a price target?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.